Does the media favor XENE or RXRX?

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 13 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.21 beat Recursion Pharmaceuticals' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CGON or RXRX?

In the previous week, Recursion Pharmaceuticals had 14 more articles in the media than CG Oncology. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat Recursion Pharmaceuticals' score of 0.33 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BLTE or RXRX?

In the previous week, Recursion Pharmaceuticals had 19 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 3 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.09 beat Recursion Pharmaceuticals' score of 0.33 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ERAS or RXRX?

In the previous week, Erasca had 13 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 35 mentions for Erasca and 22 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.33 beat Erasca's score of 0.18 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 1 Positive mention(s) 30 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Recursion Pharmaceuticals (RXRX) Competitors

$3.17 -0.14 (-4.23%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.19 +0.02 (+0.63%)

As of 05:51 AM Eastern

Compare

RXRX vs. XENE, CGON, CNTA, BLTE, and ERAS

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), and Erasca (ERAS).

How does Recursion Pharmaceuticals compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 13 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.21 beat Recursion Pharmaceuticals' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 20.06%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 155.52%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Xenon Pharmaceuticals' return on equity of -49.23% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Xenon Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	828.78	-$345.91M	-$4.70	N/A
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A

Summary

Xenon Pharmaceuticals beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

CG Oncology has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. CG Oncology's return on equity of -23.33% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

CG Oncology has higher earnings, but lower revenue than Recursion Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,581.05	-$160.99M	-$2.33	N/A
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A

In the previous week, Recursion Pharmaceuticals had 14 more articles in the media than CG Oncology. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.07 beat Recursion Pharmaceuticals' score of 0.33 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

CG Oncology presently has a consensus target price of $81.73, suggesting a potential upside of 12.85%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 155.52%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CG Oncology and Recursion Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A

In the previous week, Recursion Pharmaceuticals had 22 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 0 mentions for Centessa Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.33 beat Centessa Pharmaceuticals' score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Recursion Pharmaceuticals	Neutral

Centessa Pharmaceuticals currently has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 155.52%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Summary

Recursion Pharmaceuticals beats Centessa Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Belite Bio has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Belite Bio has higher earnings, but lower revenue than Recursion Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A

Belite Bio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Belite Bio's return on equity of -13.14% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Belite Bio currently has a consensus target price of $203.00, indicating a potential upside of 28.08%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 155.52%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 19 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Recursion Pharmaceuticals and 3 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.09 beat Recursion Pharmaceuticals' score of 0.33 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Belite Bio beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Erasca?

Erasca (NASDAQ:ERAS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

67.8% of Erasca shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Erasca has higher earnings, but lower revenue than Recursion Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Recursion Pharmaceuticals	$74.68M	22.49	-$644.76M	-$1.20	N/A

In the previous week, Erasca had 13 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 35 mentions for Erasca and 22 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.33 beat Erasca's score of 0.18 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	30 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Erasca presently has a consensus price target of $21.64, indicating a potential upside of 16.20%. Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 155.52%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Erasca has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Erasca's return on equity of -35.31% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Summary

Erasca beats Recursion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.75B	$3.57B	$6.86B	$12.98B
Dividend Yield	N/A	3.77%	2.60%	9.79%
P/E Ratio	-2.64	7.68	280.40	25.25
Price / Sales	22.49	1,175.61	560.36	77.68
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	1.48	17.07	12.94	6.09
Net Income	-$644.76M	-$12.52M	$3.49B	$347.95M
7 Day Performance	4.28%	2.34%	2.43%	3.08%
1 Month Performance	-19.95%	-5.13%	-2.86%	-3.01%
1 Year Performance	-42.15%	52.38%	75.40%	20.49%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	1.974 of 5 stars	$3.17 -4.2%	$8.10 +155.5%	-42.7%	$1.75B	$74.68M	N/A	400	Trending News Earnings Report
XENE Xenon Pharmaceuticals	2.9265 of 5 stars	$65.42 flat	$77.20 +18.0%	+86.9%	$6.32B	$7.50M	N/A	210	Positive News Upcoming Earnings
CGON CG Oncology	2.7507 of 5 stars	$69.32 -2.5%	$81.73 +17.9%	+168.8%	$6.27B	$5.07M	N/A	61	Positive News Upcoming Earnings Options Volume
CNTA Centessa Pharmaceuticals	N/A	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200	Upcoming Earnings
BLTE Belite Bio	3.4931 of 5 stars	$153.36 -1.9%	$203.00 +32.4%	+139.0%	$6.26B	N/A	N/A	10	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. XENE, CGON, CNTA, BLTE, and ERAS

How does Recursion Pharmaceuticals compare to Xenon Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to CG Oncology?

Summary

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Belite Bio?

Summary

How does Recursion Pharmaceuticals compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. XENE, CGON, CNTA, BLTE, and ERAS

How does Recursion Pharmaceuticals compare to Xenon Pharmaceuticals?

Do insiders & institutionals hold more shares of XENE or RXRX?

Does the media favor XENE or RXRX?

Do analysts prefer XENE or RXRX?

Which has more risk & volatility, XENE or RXRX?

Is XENE or RXRX more profitable?

Which has stronger valuation and earnings, XENE or RXRX?

Summary

How does Recursion Pharmaceuticals compare to CG Oncology?

Is CGON or RXRX more profitable?

Which has higher earnings & valuation, CGON or RXRX?

Does the media favor CGON or RXRX?

Which has more volatility and risk, CGON or RXRX?

Do analysts recommend CGON or RXRX?

Do institutionals and insiders hold more shares of CGON or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Which has more risk & volatility, CNTA or RXRX?

Which has higher earnings & valuation, CNTA or RXRX?

Does the media refer more to CNTA or RXRX?

Do analysts rate CNTA or RXRX?

Do insiders & institutionals hold more shares of CNTA or RXRX?

Is CNTA or RXRX more profitable?

Summary

How does Recursion Pharmaceuticals compare to Belite Bio?

Which has more risk & volatility, BLTE or RXRX?

Do insiders & institutionals have more ownership in BLTE or RXRX?

Which has better valuation & earnings, BLTE or RXRX?

Is BLTE or RXRX more profitable?

Do analysts rate BLTE or RXRX?

Does the media prefer BLTE or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Erasca?

Do insiders and institutionals believe in ERAS or RXRX?

Which has better earnings & valuation, ERAS or RXRX?

Does the media refer more to ERAS or RXRX?

Which has more volatility and risk, ERAS or RXRX?

Do analysts prefer ERAS or RXRX?

Is ERAS or RXRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools